| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Keryx Biopharmaceuticals, Inc. |
| 216 Jaffa Road, Jerusalem, Israel 94383 |
| Business Description | The Company is a pioneer in the post-genomics era, applying data from the human genome for the systematic discovery of new drugs. |
|
Filing Information Not yet | |||
| To Trade As | KERX (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 5/19/00 |
| Domestic Shares Filed | 4,600,000 | Filing Range | $10.00 - $12.00 |
| Foreign Shares Filed | 0 | Offering Amount | $50,600,000 |
| Company Shares | 4,600,000 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | 18,800,000 |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Roth Capital Partners | Lead Manager | |
| WestLB Panmure | Co-manager |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 3 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | 3/31/99 | 3/31/00 | ||
| Revenues | - | - | 0.233 | 0.066 | 0.000 | 0.000 | 0.000 |
| Income from Oper. | - | - | -0.861 | -2.352 | -8.736 | -0.677 | -1.867 |
| Net Income | - | - | -0.882 | -2.539 | -9.003 | -0.687 | -1.839 |
| E.P.S | - | - | -0.160 | -0.470 | -1.670 | -0.130 | -0.340 |
| Revenue Growth (%) | - | - | -71.67 | -100.000 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -2.26 | -2.81 | -5.81 | ||||
| Cash Flow - Inv. | -0.38 | -0.16 | -0.67 | ||||
| Cash Flow - Fin. | 2.12 | 6.97 | 10.59 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 3/31/00 | Financial Ratios | ||||
| Total Assets | 4.95 | Current Assets | 4.38 | Current Ratio | 11.10 |
| Total Liab. | 0.51 | Current Liab. | 0.39 | Debt Ratio | 10.35% |
| Total Equity | 4.44 | Working Cap. | 3.98 | Debt to Equity Ratio | 0.12 |
| Cash | 4.13 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to fund clinical KRX-101 and KRX-123, to fund the discovery and further development of compounds using our KinAce platform, and to use as working capital for general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Morgan, Lewis & Bockius |
| Bank's Law Firm | Baer Marks & Upham |
| Registrar/Transfer Agent | American Stock Transfer Company |
| Auditor | KPMG Accountants N.V. |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Children's Medical Center Corporation | 5.65 | |
| Note: represents ownership of 5% or more prior to the offering. | ||